AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30188085 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 237
Study 26391623 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs), n = 5
Number of subjects: 13
Study 26391623 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drugs (AADs), n = 8
Number of subjects: 13
Study 26391623 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall AF condition
Number of subjects: 13
Study 26391623 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SR condition
Number of subjects: 13
Study 23234619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg once daily
Number of subjects: 0
Study 23234619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21663809 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (50 mg)
Number of subjects: 90
Study 21663809 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (40 mg)
Number of subjects: 90
Study 21663809 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 90
Study 19636011 — intervention group
Group type: EXPERIMENTAL
Intervention: rhITF 10 mg/mL (low dose)
Number of subjects: 99
Study 19636011 — intervention group
Group type: EXPERIMENTAL
Intervention: rhITF 80 mg/mL (high dose)
Number of subjects: 99
Study 19636011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 16179822 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 41
Study 16179822 — intervention group
Group type: COMPARATOR
Intervention: HCV-negative asthmatics (control group)
Number of subjects: 41
Study 15288082 — intervention group
Group type: EXPERIMENTAL
Intervention: Non nutritive pacifier sucking (T)
Number of subjects: 33
Study 15288082 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of Emla with non nutritive pacifier sucking (E)
Number of subjects: 33
Study 15288082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 30% saccharose solution with non nutritive pacifier sucking (S)
Number of subjects: 33
Study 15288082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 30% saccharose solution with local application of Emla and with non nutritive pacifier sucking (S + E)
Number of subjects: 33
Study 11323125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain beliefs
Number of subjects: 118
Study 11323125 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophizing
Number of subjects: 118
Study 11323125 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping
Number of subjects: 118
Study 11323125 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs
Number of subjects: 118
Study 11323125 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measure of jaw impairment
Number of subjects: 118
Study 9596385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and motivation program
Number of subjects: 93
Study 9596385 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 93
Study 8164926 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined regimen with 2.5 mg of MPA (Group A)
Number of subjects: 1724
Study 8164926 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined regimen with 5.0 mg of MPA (Group B)
Number of subjects: 1724
Study 8164926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen with 5.0 mg of MPA (Group C)
Number of subjects: 1724
Study 8164926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen with 10.0 mg of MPA (Group D)
Number of subjects: 1724
Study 8164926 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens alone (Group E)
Number of subjects: 1724
Study 2904752 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 228
Study 2904752 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 228
Study 30833373 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI score <10
Number of subjects: 0
Study 30833373 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI score ≥10
Number of subjects: 0
Study 30833373 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI score ≥10 and ADM use
Number of subjects: 0
Study 30833373 — intervention group
Group type: COMPARATOR
Intervention: No ADM use
Number of subjects: 0
Study 26293750 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 79
Study 26293750 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of depressive symptoms
Number of subjects: 79
Study 26293750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer drug-related problems
Number of subjects: 79
Study 26293750 — intervention group
Group type: EXPERIMENTAL
Intervention: No use of hard drugs within the prior 30 days
Number of subjects: 79
Study 25601341 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg once daily) plus prednisone (5 mg twice daily)
Number of subjects: 1088
Study 25601341 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 1088
Study 23835495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO₃)
Number of subjects: 120
Study 23835495 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl)
Number of subjects: 120
Study 20233897 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% CO2 inhalation for 20 minutes
Number of subjects: 12
Study 20233897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (compressed air) for 20 minutes
Number of subjects: 12
Study 20233897 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% CO2 inhalation on day 2
Number of subjects: 12
Study 20233897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (compressed air) on day 2
Number of subjects: 12
Study 19485973 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glucose levels
Number of subjects: 1324
Study 16820555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (1 to 3 mg/h for 48 hours)
Number of subjects: 240
Study 16820555 — intervention group
Group type: COMPARATOR
Intervention: Oral metoprolol (25 mg twice per day to 50 mg 3 times per day starting on the first postoperative morning)
Number of subjects: 240
Study 14509562 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 54 microg via Turbuhaler
Number of subjects: 88
Study 14509562 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 2400 microg via pMDI plus spacer
Number of subjects: 88
Study 10849056 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of lansoprazole (30 mg once daily), clarithromycin (250 mg twice daily), and amoxicillin (500 mg three times daily)
Number of subjects: 46
Study 10849056 — intervention group
Group type: COMPARATOR
Intervention: 7 days of lansoprazole (30 mg once daily), clarithromycin (250 mg twice daily), and amoxicillin (500 mg three times daily)
Number of subjects: 46
Study 9061892 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountability manipulation
Number of subjects: 0
Study 9061892 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 0
Study 8400591 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (100% soybean oil)
Number of subjects: 36
Study 8400591 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (50:50 mixture of soybean oil and medium-chain triglycerides)
Number of subjects: 36
Study 8400591 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (42.5% MCT, 50% soybean oil, and 7.5% blackcurrant seed oils)
Number of subjects: 36
Study 8400591 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 36
Study 8400591 — intervention group
Group type: COMPARATOR
Intervention: All diets
Number of subjects: 36
Study 2948143 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg
Number of subjects: 0
Study 2948143 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg
Number of subjects: 0
Study 2948143 — intervention group
Group type: COMPARATOR
Intervention: Zomepirac 100 mg
Number of subjects: 0
Study 2948143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30430515 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training in the mental image
Number of subjects: 37
Study 30430515 — intervention group
Group type: COMPARATOR
Intervention: Group 2 of reference
Number of subjects: 37
Study 27365164 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary drug concentrations after administration of a single dose of antipsychotic drugs
Number of subjects: 0
Study 27365164 — intervention group
Group type: COMPARATOR
Intervention: Venous drug concentrations after administration of a single dose of antipsychotic drugs
Number of subjects: 0
Study 24587878 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFence LV
Number of subjects: 74
Study 24587878 — intervention group
Group type: COMPARATOR
Intervention: Guardix-Sol (HA-CMC)
Number of subjects: 74
Study 22963750 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 32
Study 22963750 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF/CPC
Number of subjects: 32
Study 20547424 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 40
Study 20547424 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 40
Study 18476965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral sildenafil 100 mg (group III)
Number of subjects: 80
Study 18476965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral sildenafil 25 mg (group II)
Number of subjects: 80
Study 18476965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with PGE1 (5 microg) and oral sildenafil 100 mg (group V)
Number of subjects: 80
Study 18476965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with PGE1 (5 microg) and oral placebo (group IV)
Number of subjects: 80
Study 18476965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral placebo (group I)
Number of subjects: 80
Study 16161380 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow-cooling blanket
Number of subjects: 0
Study 16161380 — intervention group
Group type: COMPARATOR
Intervention: Waterflow-cooling blanket
Number of subjects: 0
Study 12647260 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 40
Study 12647260 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 40
Study 10867332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 87
Study 10867332 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg daily
Number of subjects: 87
Study 8892095 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro culture in T‐cell growth factor/interleukin 2 and 4-containing medium (TCGF/IL2/IL4)
Number of subjects: 21
Study 8892095 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood mononuclear cells (PBMC) expanded in TCGF/IL2/IL4
Number of subjects: 21
Study 8892095 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly obtained CSF cells stimulated directly with myelin basic protein (MBP)
Number of subjects: 21
Study 8892095 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitogen stimulation of expanded CSF cells
Number of subjects: 21
Study 8213302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient detoxification
Number of subjects: 43
Study 3476982 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental replantation
Number of subjects: 57
Study 3476982 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 29161349 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal (macular pigment optical density/MPOD) and blood serum concentrations of lutein and zeaxanthin in older adults
Number of subjects: 54
Study 29161349 — intervention group
Group type: COMPARATOR
Intervention: Younger adults (control group)
Number of subjects: 54
Study 29161349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin (L&Z)
Number of subjects: 54
Study 27312107 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of neutropenia (measured in days)
Number of subjects: 569
Study 27312107 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of sterile site infections
Number of subjects: 569
Study 26450249 — intervention group
Group type: EXPERIMENTAL
Intervention: Care home residents
Number of subjects: 708
Study 23092173 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Symptom Inventory (PSI)
Number of subjects: 143
Study 23092173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatology Life Quality Index (DLQI)
Number of subjects: 143
Study 23092173 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36v2 Acute
Number of subjects: 143
Study 23092173 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Global Assessment (PtGA)
Number of subjects: 143
Study 21134844 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐s TV ad simulation
Number of subjects: 279
Study 21134844 — intervention group
Group type: EXPERIMENTAL
Intervention: billboard simulation
Number of subjects: 279
Study 21134844 — intervention group
Group type: COMPARATOR
Intervention: no‐information condition
Number of subjects: 279
Study 18184251 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20
Study 18184251 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20
Study 18184251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 17313848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (tacrolimus + glucocorticoid)
Number of subjects: 94
Study 17313848 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (tacrolimus + mycophenolate mofetil + glucocorticoid)
Number of subjects: 94
Study 17313848 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (tacrolimus + mycophenolate mofetil + glucocorticoid + daclizumab)
Number of subjects: 94
Study 12638645 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for tobacco dependence in alcoholic smokers
Number of subjects: 0
Study 12638645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic options for tobacco dependence
Number of subjects: 0
Study 12638645 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy and 12-step approaches
Number of subjects: 0
Study 12638645 — intervention group
Group type: EXPERIMENTAL
Intervention: Further research on effective treatments
Number of subjects: 0
Study 10798820 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (25 mg once daily for 1 week, 50 mg once daily for the second week, and 100 mg once daily for the last 2 weeks)
Number of subjects: 30
Study 10798820 — intervention group
Group type: COMPARATOR
Intervention: Lithium (400 mg twice daily)
Number of subjects: 30
Study 10798820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study 7625346 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplement (SL; 300 micrograms/d, n = 14)
Number of subjects: 71
Study 7625346 — intervention group
Group type: COMPARATOR
Intervention: Placebo lactating (PL; n = 15)
Number of subjects: 71
Study 7625346 — intervention group
Group type: COMPARATOR
Intervention: Placebo formula feeding (FF; n = 18)
Number of subjects: 71
Study 2522902 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting GnRH agonist (100-500 micrograms daily)
Number of subjects: 119
Study 2522902 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting GnRH agonist (3.2 mg intramuscularly)
Number of subjects: 119
Study 2522902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GnRH-agonist/gonadotropin stimulation
Number of subjects: 119
Study 2522902 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 119
Study 331057 — intervention group
Group type: EXPERIMENTAL
Intervention: Kavain (200 mg per capsule, 2 capsules per day)
Number of subjects: 84
Study 331057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules per day)
Number of subjects: 84
Study 31787759 — intervention group
Group type: EXPERIMENTAL
Intervention: One-layer vasovasostomy with stent (n = 23)
Number of subjects: 42
Study 31787759 — intervention group
Group type: COMPARATOR
Intervention: Two-layer vasovasostomy (n = 19)
Number of subjects: 42
Study 31023363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-frequency oscillatory ventilation (nHFOV) started immediately after extubation
Number of subjects: 6
Study 31023363 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 6
Study 28296618 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus temozolomide
Number of subjects: 562
Study 28296618 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 562
Study 28296618 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus temozolomide (MGMT methylated)
Number of subjects: 562
Study 28296618 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (MGMT methylated)
Number of subjects: 562
Study 28296618 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus temozolomide (MGMT unmethylated)
Number of subjects: 562
Study 28296618 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (MGMT unmethylated)
Number of subjects: 562
Study 28296618 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 562
Study 25892513 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca[OH]2)
Number of subjects: 20
Study 25892513 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca[OH]2) + chlorhexidine (CHX)
Number of subjects: 20
Study 23349082 — intervention group
Group type: EXPERIMENTAL
Intervention: IF‐‐SRS completed in presence of therapist and results discussed immediately afterward
Number of subjects: 102
Study 23349082 — intervention group
Group type: EXPERIMENTAL
Intervention: Next Session Feedback‐‐SRS completed alone and results discussed next session
Number of subjects: 102
Study 23349082 — intervention group
Group type: COMPARATOR
Intervention: No Feedback‐‐SRS completed alone and results not available to therapist
Number of subjects: 102
Study 20197485 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-8958 (20 mg inhaled dose)
Number of subjects: 20
Study 19811351 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg LOS + 25 mg HCTZ (test formulation)
Number of subjects: 28
Study 19811351 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Hyzaar)
Number of subjects: 28
Study 16762012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TA) injection (0.5 ml at 40 mg/ml)
Number of subjects: 45
Study 16762012 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 45
Study 14770445 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa fixed dose (325 microg)
Number of subjects: 242
Study 14770445 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa weight-based dose (4.5 microg/kg)
Number of subjects: 242
Study 11423594 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS plus standard medication
Number of subjects: 0
Study 11423594 — intervention group
Group type: COMPARATOR
Intervention: Standard medication only (midazolam)
Number of subjects: 0
Study 11423594 — intervention group
Group type: COMPARATOR
Intervention: Non‐functioning TENS and standard medication
Number of subjects: 0
Study 9233202 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received at least one breastfeeding education class)
Number of subjects: 31
Study 9233202 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breastfeeding education class)
Number of subjects: 31
Study 9233202 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparous women (previously bottle-fed children)
Number of subjects: 31
Study 9233202 — intervention group
Group type: EXPERIMENTAL
Intervention: Primiparous women
Number of subjects: 31
Study 7827883 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone suture
Number of subjects: 813
Study 7827883 — intervention group
Group type: COMPARATOR
Intervention: Nylon suture
Number of subjects: 813
Study 2464223 — intervention group
Group type: EXPERIMENTAL
Intervention: BOMP (bleomycin, vincristine, mitomycin and cisplatin)
Number of subjects: 38
Study 2464223 — intervention group
Group type: COMPARATOR
Intervention: CEP (cyclophosphamide, 4'-epidoxorubicin and procarbazine)
Number of subjects: 38
Study 30178886 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy diet
Number of subjects: 108
Study 30178886 — intervention group
Group type: COMPARATOR
Intervention: Nondairy diet
Number of subjects: 108
Study 26559713 — intervention group
Group type: EXPERIMENTAL
Intervention: Why-to-quit advertisements (graphic imagery and personal testimonial)
Number of subjects: 354
Study 26559713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation cognitions (positive)
Number of subjects: 354
Study 26559713 — intervention group
Group type: COMPARATOR
Intervention: Nicotine dependence level
Number of subjects: 354
Study 25494967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 2000 or 500 mg
Number of subjects: 32
Study 25494967 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (ivMP) 7.5 g
Number of subjects: 32
Study 24289512 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolised care (two experimental approaches)
Number of subjects: 0
Study 24289512 — intervention group
Group type: COMPARATOR
Intervention: Usual 'wild type' care
Number of subjects: 0
Study 22018131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (20 mcg ethinyl estradiol/100 mcg levonorgestrel or 30 mcg ethinyl estradiol/150 mcg levonorgestrel)
Number of subjects: 33
Study 22018131 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive vaginal rings (daily release of 15 mcg ethinyl estradiol/120 mcg etonogestrel)
Number of subjects: 33
Study 22018131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills
Number of subjects: 33
Study 22018131 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive vaginal rings
Number of subjects: 33